Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
Conditions
Keywords
Dermastudy, GHSAD, GHRSD
Brief summary
The Global Healthcare Study on Atopic Dermatitis (GHSAD) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with atopic dermatitis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
Detailed description
The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.
Interventions
None listed
Sponsors
Julia Tatjana Maul
University of Zurich
University Hospital, Zürich
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed General Consent Form, or equivalent document * Confirmed diagnosis of Atopic Dermatitis
Exclusion criteria
* Inability to provide informed consent. * Datasets with ambiguous or unclear diagnosis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Eczema Area and Severity Index (EASI) | Baseline and follow-up visits every 6-12 months for up to 5 years. | Clinician-assessed measure of atopic dermatitis severity based on extent and severity of eczema signs; total score ranges from 0 to 72, with higher scores indicating more severe disease. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SCORing Atopic Dermatitis (SCORAD) | Baseline and follow-up visits every 6-12 months for up to 5 years. | Clinician-assessed measure of atopic dermatitis severity incorporating extent, intensity, and subjective symptoms; total score ranges from 0 to 103, with higher scores indicating more severe disease. |
| Dermatology Life Quality Index (DLQI) | Baseline and follow-up visits every 6-12 months for up to 5 years. | Patient-reported measure of dermatology-specific quality of life; total score ranges from 0 to 30, with higher scores indicating greater impairment. |
| Patient-Oriented Eczema Measure (POEM) | Baseline and follow-up visits every 6-12 months for up to 5 years. | Patient-reported measure of atopic dermatitis symptoms and disease burden; total score ranges from 0 to 28, with higher scores indicating more severe disease. |
| Peak Pruritus Numerical Rating Scale (PP-NRS) | Baseline and follow-up visits every 6-12 months for up to 5 years. | Patient-reported assessment of peak itch severity on a numerical rating scale from 0 (no itch) to 10 (worst imaginable itch). |
| Physician Global Assessment (PGA) | Baseline and follow-up visits every 6-12 months for up to 5 years. | Clinician-assessed global measure of atopic dermatitis severity on a scale from 0 (clear) to 4 (severe). |
| Body Surface Area (BSA) | Baseline and follow-up visits every 6-12 months for up to 5 years. | Percentage of total body surface area affected by atopic dermatitis, ranging from 0% to 100%. |
| Patient-reported Numerical Rating Scale (NRS) for atopic dermatitis severity | Baseline and follow-up visits every 6-12 months for up to 5 years. | Patient-reported assessment of overall atopic dermatitis severity on a numerical rating scale from 0 (no disease) to 10 (most severe disease imaginable). |
Countries
Switzerland
Contacts
CONTACTJulia-Tatjana Maul, Prof. Dr. med.
CONTACTJohannes Didaskalu
PRINCIPAL_INVESTIGATORJulia-Tatjana Maul, Prof. Dr. med.
University of Zurich
Outcome results
None listed